- Ramsay Health’s net income for the fiscal year is A$888.7 million, compared to A$298.1 million last year.
- The final dividend per share has increased to A$0.400 from A$0.25 in the previous year.
- Total revenues and other income have risen to A$16.77 billion, showing a 9.4% year-over-year increase.
- The company currently anticipates growth in net profit after tax (NPAT) from continuing operations in the fiscal year 2025.
- Market sentiment includes 5 buy recommendations, 10 hold recommendations, and 1 sell recommendation.
Ramsay Health Care on Smartkarma
Analysts on Smartkarma, like David Blennerhassett, have been closely monitoring Ramsay Health Care. In his recent report titled “Private Equity Examining Ramsay Health (RMC AU). Again.“, Blennerhassett highlights that Ramsay’s share price has faced significant challenges. Despite the FY24 earnings estimates aligning with FY22 figures, the market has been volatile. KKR’s previous offer of A$88.00/share, well above the current price, showcases the potential value in Ramsay Health Care. However, recent events, including weaker than expected FY24 earnings and write-downs in its European/UK operations, have caused further price declines, leaving the stock significantly below KKR’s offer.
Media reports indicate a renewed interest from private equity firms in Ramsay Health Care, reflecting the ongoing evaluation of the company’s financial health and potential for investment. With Ramsay Health Care‘s stock price under pressure and private equity firms conducting diagnostic assessments, the market sentiment remains uncertain. Investors are keeping a close watch on how Ramsay Health Care navigates through these challenges and whether potential opportunities, as identified by analysts like David Blennerhassett, may come to fruition.
A look at Ramsay Health Care Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 3 | |
Dividend | 2 | |
Growth | 5 | |
Resilience | 2 | |
Momentum | 3 | |
OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking ahead, Ramsay Health Care, a company that provides a range of health care services, has shown a promising long-term outlook based on Smartkarma Smart Scores. With a strong focus on growth, Ramsay Health Care scored a high 5 in this category, indicating positive prospects for expansion and development. Additionally, the company received a decent score of 3 for both value and momentum, suggesting a well-rounded performance in terms of its financial standing and market trends. However, Ramsay Health Care scored lower in resilience and dividend with scores of 2, signaling areas that may require attention to ensure sustainable operations and investor returns.
Ramsay Health Care Ltd., operating health care facilities in Australia, Indonesia, and Europe, has demonstrated a solid growth potential as reflected in its Smartkarma Smart Scores. With a strong emphasis on providing private hospital services and a variety of specialized treatments including rehabilitation and psychiatric care, Ramsay Health Care positions itself as a key player in the healthcare industry. While the company exhibits positive momentum and value, addressing resilience and dividend factors could further enhance its long-term performance and investor appeal.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars